SEAGULL HEALTH
Your health,We care!
Vebreltinib Enteric Capsules is the only First-in-class targeted drug in China that simultaneously covers three indications: MET exon 14 skipping mutation, MET amplification non-small cell lung cancer, and glioma.
AuthenticGuaranteeFast DeliveryPrivacy The contraindicated populations for vebreltinib a targeted therapy drug, mainly include those allergic to the drug components, patients with severe he···【Read More】
Update: 03 Feb,2026Source: Haiou HealthViews: 74
vebreltinib is a targeted therapy agent for specific gene mutations (e.g., MET exon 14 skipping mutation), primarily indicated for non-small cell lung···【Read More】
Update: 03 Feb,2026Source: Haiou HealthViews: 85
The recommended usual dose of vebreltinib is 2 capsules (50 mg per capsule) taken orally once daily, and the specific dosage must be adjusted strictly···【Read More】
Update: 03 Feb,2026Source: Haiou HealthViews: 74
Vebreltinib Enteric-coated Capsules is a targeted therapy agent primarily indicated for the treatment of malignant tumors such as non-small cell lung ···【Read More】
Update: 03 Feb,2026Source: Haiou HealthViews: 74
Vebreltinib is an oral small-molecule MET inhibitor, primarily indicated for the treatment of patients with advanced non-small cell lung cancer (NSCLC···【Read More】
Update: 03 Feb,2026Source: Haiou HealthViews: 74
vebreltinib is an oral tyrosine kinase inhibitor (TKI) primarily indicated for the treatment of non-small cell lung cancer (NSCLC) harboring specific ···【Read More】
Update: 03 Feb,2026Source: Haiou HealthViews: 71
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH
